补充虾青素作为腹膜透析大鼠潜在的抗纤维化药物

IF 0.2 Q4 UROLOGY & NEPHROLOGY
R. Dewi, Bambang Purwanto, B. Wasita, Vitri Widyaningsih, R. Cilmiaty, S. Soetrisno, R. Febrinasari, Mahatma Chakra Wardana, M. T. Giani, Indah Sagitaisna Putri
{"title":"补充虾青素作为腹膜透析大鼠潜在的抗纤维化药物","authors":"R. Dewi, Bambang Purwanto, B. Wasita, Vitri Widyaningsih, R. Cilmiaty, S. Soetrisno, R. Febrinasari, Mahatma Chakra Wardana, M. T. Giani, Indah Sagitaisna Putri","doi":"10.34172/jrip.2023.32156","DOIUrl":null,"url":null,"abstract":"Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis. Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD. Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination. Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P<0.05). However, there was no significant difference in the mean fibrosis thickness based on astaxanthin duration (P>0.05). Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Astaxanthin supplementation as a potential anti-fibrotic agent in peritoneal dialysis rats\",\"authors\":\"R. Dewi, Bambang Purwanto, B. Wasita, Vitri Widyaningsih, R. Cilmiaty, S. Soetrisno, R. Febrinasari, Mahatma Chakra Wardana, M. T. Giani, Indah Sagitaisna Putri\",\"doi\":\"10.34172/jrip.2023.32156\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis. Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD. Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination. Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P<0.05). However, there was no significant difference in the mean fibrosis thickness based on astaxanthin duration (P>0.05). Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.\",\"PeriodicalId\":16950,\"journal\":{\"name\":\"Journal of Renal Injury Prevention\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Injury Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jrip.2023.32156\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2023.32156","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介腹膜透析(PD)是慢性肾脏病(CKD)的推荐治疗方法。腹膜透析过程中持续接触透析液会导致腹膜纤维化,其特征是腹膜的形态和功能发生变化。虾青素被认为具有强大的抗氧化和抗炎特性,具有良好的抗纤维化效果,可抑制腹膜纤维化中的腹膜厚度。研究目的本研究旨在探讨补充虾青素对腹膜透析模型大鼠组织学特征的影响,从而确定虾青素是一种潜在的腹膜透析抗纤维化药物。材料和方法:本研究采用实验室实验研究,只设试验后对照组。32只雄性大鼠被随机分为四组。两组为对照组,两组为治疗组。阴性对照组(NC)腹腔注射灭菌的 aquadest,阳性对照组(PC)腹腔注射 4.25% 的透析液。治疗组 1(T1)给予透析液 4.25%注射液 IP 和虾青素 0.216 毫克补充剂 14 天,治疗组 2(T2)给予透析液 4.25%注射液 IP 和虾青素 0.216 毫克补充剂 21 天。然后收集腹膜组织并准备进行组织学检查。结果显示补充虾青素可预防CKD模型大鼠腹膜纤维化的发展(P0.05)。结论虾青素可减少腹膜纤维化模型大鼠的腹膜厚度。这项研究的相关结论是虾青素具有潜在的抗腹膜纤维化作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Astaxanthin supplementation as a potential anti-fibrotic agent in peritoneal dialysis rats
Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis. Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD. Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination. Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P<0.05). However, there was no significant difference in the mean fibrosis thickness based on astaxanthin duration (P>0.05). Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Renal Injury Prevention
Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-
CiteScore
1.60
自引率
0.00%
发文量
36
期刊介绍: The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信